Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Millard NE, De Braganca KC (2016) Medulloblastoma. J Child Neurol 31(12):1341–53. https://doi.org/10.1177/0883073815600866. Epub 2015 Sep 2. Erratum in: J Child Neurol. 2016 Sep 15

Packer RJ, Cogen P, Vezina G, Rorke LB (1999) Medulloblastoma: clinical and biologic aspects. Neuro Oncol 1(3):232–250. https://doi.org/10.1093/neuonc/1.3.232

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huybrechts S, Le Teuff G, Tauziède-Espariat A, Rossoni C, Chivet A, Indersie É, Varlet P, Puget S, Abbas R, Ayrault O, Guerrini-Rousseau L, Grill J, Valteau-Couanet D, Dufour C (2020) Prognostic clinical and biologic features for overall survival after relapse in childhood medulloblastoma. Cancers (Basel) 13(1):53. https://doi.org/10.3390/cancers13010053

Article  CAS  PubMed  Google Scholar 

Zhang B (2010) CD73: a novel target for cancer immunotherapy. Cancer Res 70(16):6407–6411. https://doi.org/10.1158/0008-5472.CAN-10-1544

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1

Article  PubMed  Google Scholar 

Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD (2017) Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31(6):737–754.e6

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF (2015) Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res 3(3):254–265. https://doi.org/10.1158/2326-6066.CIR-14-0018

Article  CAS  PubMed  Google Scholar 

Pulte D, Furman RR, Broekman MJ, Drosopoulos JH, Ballard HS, Olson KE, Kizer JR, Marcus AJ (2011) CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 11(4):367–372. https://doi.org/10.1016/j.clml.2011.06.005

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hayes GM, Cairns B, Levashova Z, Chinn L, Perez M, Theunissen JW, Liao-Chan S, Bermudez A, Flory MR, Schweighofer KJ, van der Horst EH (2015) CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. Am J Transl Res 7(6):1181–8

PubMed  PubMed Central  Google Scholar 

Braganhol E, de Andrade GPB, Santos GT, Stefani MA (2023) ENTPD1 (CD39) and NT5E (CD73) expression in human glioblastoma: an in silico analysis. Purinergic Signal. https://doi.org/10.1007/s11302-023-09951-0

Article  PubMed  PubMed Central  Google Scholar 

García-Rocha R, Monroy-García A, Carrera-Martínez M, Hernández-Montes J, Don-López CA, Weiss-Steider B, Monroy-Mora KA, Ponce-Chavero MLÁ, Montesinos-Montesinos JJ, Escobar-Sánchez ML, Castillo GM, Chacón-Salinas R, Vallejo-Castillo L, Pérez-Tapia SM, Mora-García ML (2022) Evidence that cervical cancer cells cultured as tumorspheres maintain high CD73 expression and increase their protumor characteristics through TGF-β production. Cell Biochem Funct 40(7):760–772. https://doi.org/10.1002/cbf.3742. (Erratum in: Cell Biochem Funct. 2022 Dec;40(8):960.)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin D, Wei R, Huang K, Wang R, Ding H, Yao Z, Xi P, Li S (2023) Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-023-04703-4

Article  PubMed  PubMed Central  Google Scholar 

Xu YP, Zhou YQ, Zhao YJ, Zhao Y, Wang F, Huang XY, Guo CY (2021) High level of CD73 predicts poor prognosis of intrahepatic cholangiocarcinoma. J Cancer 12(15):4655–4660. https://doi.org/10.7150/jca.51038

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xia C, Yin S, To KKW, Fu L (2023) CD39/CD73/A2AR pathway and cancer immunotherapy. Mol Cancer 22(1):44. https://doi.org/10.1186/s12943-023-01733-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao ZW, Wang HP, Lin F, Wang X, Long M, Zhang HZ, Dong K (2017) CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity. BMC Cancer 17(1):135. https://doi.org/10.1186/s12885-017-3128-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cappellari AR, Rockenbach L, Dietrich F, Clarimundo V, Glaser T, Braganhol E, Abujamra AL, Roesler R, Ulrich H, Battastini AM. Characterization of ectonucleotidases in human medulloblastoma cell lines: ecto-5'NT/CD73 in metastasis as potential prognostic factor. PLoS One. 2012;7(10):e47468. https://doi.org/10.1371/journal.pone.0047468. Epub 2012 Oct 18. Erratum in: PLoS One. 2012;7(11): https://doi.org/10.1371/annotation/0e219081-9218-480c-aa54-1142a68aed14.. Battastini, Ana Maria liveira [corrected to Battastini, Ana Maria Oliveira].

Ferretti E, Horenstein AL, Canzonetta C, Costa F, Morandi F (2019) Canonical and non-canonical adenosinergic pathways. Immunol Lett 205:25–30. https://doi.org/10.1016/j.imlet.2018.03.007

Article  CAS  PubMed  Google Scholar 

Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, Zito A, Serra S, Malavasi F (2013) A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2(9):e26246. https://doi.org/10.4161/onci.26246

Article  PubMed  PubMed Central  Google Scholar 

Leone RD, Emens LA (2018) Targeting adenosine for cancer immunotherapy. J Immunother Cancer 6(1):57. https://doi.org/10.1186/s40425-018-0360-8

Article  PubMed  PubMed Central  Google Scholar 

Menyhárt O, Giangaspero F, Győrffy B (2019) Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas. J Hematol Oncol 12:29. https://doi.org/10.1186/s13045-019-0712-y

Article  PubMed  PubMed Central  Google Scholar 

Kijima N, Kanemura Y (2016) Molecular classification of medulloblastoma. Neurol Med Chir (Tokyo) 56(11):687–697. https://doi.org/10.2176/nmc.ra.2016-0016

Article  PubMed  Google Scholar 

Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, Castelo-Branco P, Baskin B, Ray PN, Bouffet E, von Bueren AO, Jones DT, Northcott PA, Kool M, Sturm D, Pugh TJ, Pomeroy SL, Cho YJ, Pietsch T, Gessi M, Rutkowski S, Bognar L, Klekner A, Cho BK, Kim SK, Wang KC, Eberhart CG, Fevre-Montange M, Fouladi M, French PJ, Kros M, Grajkowska WA, Gupta N, Weiss WA, Hauser P, Jabado N, Jouvet A, Jung S, Kumabe T, Lach B, Leonard JR, Rubin JB, Liau LM, Massimi L, Pollack IF, Shin Ra Y, Van Meir EG, Zitterbart K, Schüller U, Hill RM, Lindsey JC, Schwalbe EC, Bailey S, Ellison DW, Hawkins C, Malkin D, Clifford SC, Korshunov A, Pfister S, Taylor MD, Tabori U (2013) Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31(23):2927–2935. https://doi.org/10.1200/JCO.2012.48.5052

Article  PubMed  PubMed Central  Google Scholar 

Cappellari AR et al (2015) Ecto-5’-nucleotidase overexpression reduces tumor growth in a xenograph medulloblastoma model. PLoS One 10(10):e0140996. https://doi.org/10.1371/journal.pone.0140996

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elaskalani O, Domenichini A, AbdolRazak NB, Dye DE, Falasca M, Metharom P (2020) Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT pathway in pancreatic cancer cells. Cancers (Basel). 12(1):250. https://doi.org/10.3390/cancers12010250

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ballerini P, Dovizio M, Bruno A, Tacconelli S, Patrignani P (2018) P2Y12 receptors in tumorigenesis and metastasis. Front Pharmacol 2(9):66. https://doi.org/10.3389/fphar.2018.00066

Article  CAS  Google Scholar 

Strasenburg W, Jóźwicki J, Durślewicz J, Kuffel B, Kulczyk MP, Kowalewski A, Grzanka D, Drewa T, Adamowicz J (2022) Tumor cell-induced platelet aggregation as an emerging therapeutic target for cancer therapy. Front Oncol 23(12):909767. https://doi.org/10.3389/fonc.2022.909767

Article